淀粉微载体的制备及对CHO-K1细胞培养的初步应用

以普通市售马铃薯淀粉为原材料,在常温下利用W/O乳化方法制备了交联淀粉微球,并以二乙胺基乙基修饰了微球的表面电荷。同时研究了制备淀粉微球的制备工艺和改性工艺,成功制备了适合细胞培养用的淀粉微载体。利用扫描电镜(SEM)、红外(FT-IR)、X射线衍射仪(XRD)对微球进行了表征。结果表明,最佳制备条件为:淀粉溶液浓度为7%,搅拌速度为500 rpm,交联剂用量为8%,水油相体积比1∶6;微球表面修饰最佳条件为:加入微球质量2倍体积的3.5 mol/L NaOH溶液和2.5 mol/L DEAE-HCl溶液,60℃密闭反应4 h。对比Cytodex-1微载体,培养CHO-K1细胞至144 h时,淀粉微载体表面细胞密度达到1.8×10~6cells/mL,且两者培养效果相似,表明了自制淀粉微载体是一种潜在的贴壁细胞培养用高分子材料。     

载荷壳聚糖微球的海藻酸钠水凝胶的制备

目的:在支架材料上引入具有控释行为的微球,旨在通过微球包裹生长因子,通过生长因子的缓慢释放从而促进种子细胞的生长分化。方法:本实验通过在海藻酸钠水凝胶中负载具有控释功能的壳聚糖微球,并通过在微球中包载溶菌酶从而达到控制壳聚糖降解速率的功效。实验研究了不同搅拌速度下壳聚糖微球的形貌及粒径大小,通过扫描电镜对壳聚糖微球及复合支架的形貌进行了观察,通过紫外光吸收法测试了微球的载药量及包封率,并研究了壳聚糖微球在体外的降解行为等。结果:制备的壳聚糖微球表面较光滑,溶菌酶的包封率在25.78%-41.89%之间,载药量在15.20%-24.44%之间。包封溶菌酶的微胶囊在降解9天后壳聚糖分子量下降了70.40%,载荷微球的复合凝胶孔洞增多,孔洞大小均匀。结论:此复合材料有望作为载荷软骨相关生长因子的支架模型,从而解决软骨组织工程中种子细胞匮乏的问题。     

固定化微球降解土壤中PAEs效果及影响因素

旨为研究土壤邻苯二甲酸酯污染修复中,固定化微球降解土壤中邻苯二甲酸酯的效果及影响因素。以海藻酸钠为载体,采用包埋法对课题组前期提取的微小杆菌进行固定化,比较固定化微球和游离菌降解土壤中邻苯二甲酸酯(Phthalates esters,PAEs)的效果及pH、温度、重金属、无机盐等对降解菌降解目标物的影响。结果显示:(1)在土壤环境相同条件下,固定化微球对邻苯二甲酸二甲酯(Dimethyl ortho-phthalate,DMP)、邻苯二甲酸二正丁酯(Di-n-butyl ortho-phthalate,DnBP)和邻苯二甲酸二(2-乙基己)酯(Bis(2-ethylhexyl)ortho-phthalate,DEHP)的降解效果高于游离菌,DMP在7 d可降解完全,DnBP在10 d内可降解完全,DEHP在20 d降解率63.73%;而游离菌则在15 d内完全降解DMP,20 d内完全降解DnBP,DEHP在20 d降解率48.77%;(2)不同pH值时,固定化微球对DMP、DnBP、DEHP的降解率均高于游离菌,pH9时,固定化微球对于DMP、DnBP、DEHP的降解率最高分别为96.81%、89.39%、58.35%;(3)不同温度,固定化微球对DMP、DnBP、DEHP的降解率也均高于游离菌,温度为30℃时,固定化微球对于DMP、DnBP、DEHP的降解效率达到最高,分别为96.27%、89.19%、59.01%;(4)重金属使游离菌对DMP、DnBP、DEHP降解率下降较多,而使固定化微球对DMP、DnBP的降解率仅下降了16.35%、9.95%,DEHP不仅没有降低,反而增加2.49%,说明重金属对游离菌起到很强的抑制作用,但对于固定化微球的降解效果影响较小;(5)盐碱条件下,中性盐极大降低了游离菌和固定化微球降解DMP、DnBP、DEHP的降解能力,碱性盐和混合盐对降解菌影响较小,且增强了固定化微球对DnBP、DEHP的降解能力。固定化微球降解PAEs效果明显高于游离菌,对外界环境有更好的适应能力,且对重金属、无机盐污染环境有一定的抵御能力。     

载荷壳聚糖微球的海藻酸钠水凝胶的制备

目的：在支架材料上引入具有控释行为的微球,旨在通过微球包裹生长因子,通过生长因子的缓慢释放从而促进种子细胞的生长分化。方法：本实验通过在海藻酸钠水凝胶中负载具有控释功能的壳聚糖微球,并通过在微球中包栽溶茵酶从而达到控制壳聚糖降解速率的功效。实验研究了不同搅拌速度下壳聚糖微球的形貌及粒径大小,通过扫描电镜对壳聚糖微球及复合支架的形貌进行了观察,通过紫外光吸收法测试了微球的载药量及包封率,并研究了壳聚糖微球在体外的降解行为等。结果：制备的壳聚糖微球表面较光滑,溶菌酶的包封率在25．78％41．89％之间,载药量在15．20％-24．44％之间。包封溶茵酶的微胶囊在降解9天后壳聚糖分子量下降了70．40％,载荷微球的复合凝胶孔洞增多,孔洞大小均匀。结论：此复合材料有望作为栽荷软骨相关生长因子的支架模型,从而解决软骨组织工程中种子细胞匮乏的问题。     

多孔淀粉负载青蒿素微球的溶出、生物利用度和组织分布研究

探讨多孔淀粉负载青蒿素微球(ART-PS)在体外溶出实验中,相比于青蒿素原药的溶出效果以及在大鼠体内的生物利用度和组织分布规律。在体外溶出实验中,分别在水、人工胃液和人工肠液三种溶出介质中,与青蒿素原药的溶出效果进行比较分析。在体内生物利用度实验中,通过对18只大鼠分别灌胃青蒿素原药与多孔淀粉负载青蒿素微球后,检测不同时间点的血药浓度,考察药物在大鼠体内的吸收和代谢差异。在组织分布规律的研究中,对98只大鼠分别灌胃多孔淀粉负载青蒿素微球和青蒿素原药,在不同时间点检测大鼠心、肝、脾、肺、肾、脑,共6个组织器官中的药物浓度。多孔淀粉负载青蒿素微球的体外溶出率在水、人工胃液、人工肠液中分别是青蒿素原药的4.04、3.59和3.82倍。多孔淀粉负载青蒿素微球在大鼠体内的血药浓度明显高于青蒿素原药,生物利用度提高为青蒿素原药的2.90倍。在组织分布的结果中,多孔淀粉负载青蒿素微球和青蒿素原药都主要分布在心脏和肝脏中,其中多孔淀粉负载青蒿素微球在不同时间各个组织中的相应含量都比原药高。多孔淀粉负载青蒿素微球相比于青蒿素原药,在体外的溶出效果更好,在体内的吸收释放效果更佳,在各组织器官中的药物含量明显高于原药,为解决青蒿素因难溶于水而在实际应用中受限提供了重要的理论依据。     

微泡菌属菌株YPW1和YPW16多糖降解特性分析

【背景】海洋环境中分离到的微泡菌属菌株具有多糖降解能力,在环境中可以作为糖类代谢的重要执行者参与海洋碳循环过程。【目的】测定2株微泡菌属菌株的多糖降解活性,通过与微泡菌属其他菌株基因组比较分析2株菌的多糖降解基因特征。【方法】通过3,5-dinitrosalicylicacid(DNS)定糖法测定多糖降解活性,同时利用高通量测序技术对菌株基因组序列进行测定与组装,并与其他基因组注释结果进行比较分析。【结果】分离得到2株微泡菌属菌株YPW1和YPW16,二者均为潜在新种。结果表明,菌株YPW1能够降解琼胶、褐藻胶、果胶、几丁质、木聚糖、淀粉、普鲁兰等7种多糖,而菌株YPW16仅可降解淀粉和普鲁兰。基因组分析表明,YPW1具有上述7种多糖的降解酶基因,但菌株YPW16只具有淀粉酶与普鲁兰酶降解基因。相较于其他微泡菌属菌株,菌株YPW1多糖降解范围、多糖降解酶基因种类与丰度较高,但菌株YPW16多糖降解范围却较为狭窄。由此可知,多糖降解酶基因在微泡菌属基因组中的分布差异性较大。【结论】本研究为微泡菌属提供了2株潜在的新型菌株资源,为生物多糖降解提供了生化工具,也为研究微泡菌属菌株中多糖降解基...     

缓释微球疫苗的研究进展

缓释微球疫苗是近年来研制和开发新剂型疫苗的一大热点。本文概述了微球制备工艺、体外降解机理、靶向分布及微球疫苗的动物学实验,主要讨论了口服缓释微球疫苗的优点。应用该技术可望实现将多剂疫苗改为具有同等效力的单剂疫苗的目标     

萘普生缓释微球制备工艺及性能研究

本文利用壳聚糖和海藻酸钠通过复凝聚法将萘普生制成微球,研究成球的最佳制备工艺条件及载药微球性能,制备了可生物相容,自然降解无毒的载药微球。实验中,以微球的药物包封率为制备工艺优化指标,通过正交实验得出微球的最佳制备工艺条件为:壳聚糖浓度∶海藻酸钠浓度为1:1,pH值为4.0,搅拌速度为300rpm,反应温度为35℃。以最佳制备工艺条件制备的含药微球,重现性好,工艺稳定,同时体外溶出实验表明,该微球具有较好的缓释作用。     

多孔淀粉负载青蒿素微球的抗肿瘤活性研究

探讨多孔淀粉负载青蒿素微球(ART-PS)与青蒿素原药(ART)在不同浓度下的抗肿瘤活性,以及分别联合全铁转铁蛋白后对肿瘤细胞的生长抑制作用。在体外实验中,取对数生长期的人肝癌细胞和正常肝细胞接种于96孔板中,不同浓度(0、50、100、150、200μmol·L^-1)给药处理24h后,用MTT法分别检测多孔淀粉负载青蒿素微球与青蒿素原药对细胞的生长抑制作用。MTT结果显示,同等处理浓度下,多孔淀粉负载青蒿素微球对肿瘤细胞Hep G2和SMMC-7721的抑制效果都高于青蒿素原药,但与盐酸阿霉素相比,都具有较低的细胞毒性,对正常细胞HL7702的毒副作用非常低,结果与分别联合全铁转铁蛋白后对肿瘤细胞的生长抑制作用一致。多孔淀粉负载青蒿素微球对人肝癌细胞的增殖有明显的抑制作用,效果优于青蒿素原药,并对正常肝细胞的毒副作用非常低,为青蒿素在治疗癌症的应用与研究提供了重要的参考依据。     

一种新型的基因传递系统:PLGA微球

乳酸聚乙醇酸是一类可生物降解的高分子聚合材料,通过其自身降解来调节药物释放．具有良好的生物相容性。包裹或吸附药物而制成的微球多用于药物的缓释给药系统,近几年来将这一系统应用于包裹基因。该文介绍乳酸聚乙醇酸基因微球的制备方法、主动脱逸特性等。     

Synthetic microspheres transferred to the rat oviduct on day 1 of pregnancy mimic the transport of native ova

Microspheres of various materials and diameters were transferred microsurgically to the rat oviduct on Day 1 of pregnancy and autopsies were done at various times thereafter up to Day 10 to assess the recovery and segmental distribution of microspheres and eggs in the genital tract or the viability of embryos. The number and distribution of eggs in the treated and control sides after unilateral transfers were not different on Day 4 and 5 and the number of embryos implanted on Day 10 was not significantly affected after bilateral transfers. The segmental distribution of eggs and starch microspheres within the oviduct on Days 2, 3 or 4 showed that both are transported partly intermingled from ampulla to uterus. When microspheres of poly(DL-lactide-co-glycolide), starch, dextran or dextran blue were transferred, their distribution in the genital tract in the morning of Day 5 showed that poly(DL-lactide-co-glycolide) and dextran microspheres stayed longer in the oviduct while starch and dextran blue microspheres were transported to the uterus at the same time as the eggs. Transfer of starch microspheres of 40-60 microns to one oviduct and 180-200 microns in diameter to the opposite oviduct showed that distribution on one side was nearly identical to that of the other side from Days 2 to 5. We conclude that the behaviour of synthetic surrogate ova in rats differs from that in rabbits. The rat oviduct does not change the rate of transport of native eggs following transfer of synthetic surrogate ova.(ABSTRACT TRUNCATED AT 250 WORDS)     

Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone

The purpose of this research was to assess the physicochemical properties of a controlled release formulation of recombinant human growth hormone (rHGH) encapsulated in poly(D,L-lactide-co-glycolide) (PLGA) composite microspheres. rHGH was loaded in poly(acryloyl hydroxyethyl) starch (acHES) microparticles, and then the protein-containing microparticles were encapsulated in the PLGA matrix by a solvent extraction/evaporation method. rHGH-loaded PLGA microspheres were also prepared using mannitol without the starch hydrogel microparticle microspheres for comparison. The detection of secondary structure changes in protein was investigated by using a Fourier Transfer Infrared (FTIR) technique. The composite microspheres were spherical in shape (44.6±2.47 μm), and the PLGA-mannitol microspheres were 39.7±2.50 μm. Drug-loading efficiency varied from 93.2% to 104%. The composite microspheres showed higher overall drug release than the PLGA/mannitol microspheres. FTIR analyses indicated good stability and structural integrity of HGH localized in the microspheres. The PLGA-acHES composite microsphere system could be useful for the controlled delivery of protein drugs.     

Changes in starch structure during manufacturing of starch microspheres for use in parenteral drug formulations: Effects of temperature treatment

Starch microspheres were produced by emulsification of a starch dispersion in an aqueous polyethylene glycol (PEG) solution. Crystalline/ordered structure was formed within these starch droplets during incubation at 6 °C for 25 h followed by incubation at 37 °C for 28 h. After incubation at 37 °C the crystalline structure in the samples was of type B. The crystallization process of microspheres was compared with crystallization in a model system. The crystalline structure of the microspheres melted at temperatures almost 20 °C lower than in the model system incubated under the same conditions, as determined by differential scanning calorimetry. It was thus concluded that the crystallization process within microspheres was different than that of bulk starch and the ability of the starch molecules to reorganize themselves within the dispersed starch phase of an aqueous two-phase system at the higher incubation temperature was limited. It was also observed that the presence of PEG or carbonate buffer protected the molecular order formed by the starch molecules during incubation from breakdown during freeze-drying.     

Starch-based microspheres for sustained-release of curcumin: Preparation and cytotoxic effect on tumor cells

Curcumin (CUR) has been proved to be highly cytotoxic against different tumor cell lines. However, its poor solubility in aqueous medium and fast degradation in physiological pH are the common drawbacks preventing its efficient practical use. Herein, we report the development of original microspheres based on the biopolymer starch crosslinked with N,N-methylenebisacrylamide (MBA) to be applied as an efficient delivering system for CUR. The starch-based microspheres showed high loading efficiency even in loading solution with different CUR concentrations. In vitro release assays data showed that the CUR release is governed by anomalous transport (n = 0.73) and it is pH-dependent. Cytotoxicity assays showed that starch microspheres could improve the cytotoxicity of CUR toward Caco-2 and HCT-116 tumor cell lines up to 40 times than that found for pure CUR. This behavior was attributed to the slowly and sustained release of CUR from the microspheres.     

Variation of incorporation of [3H]orotic acid into the nucleotide and RNA fractions of different parts of the same liver lobe in the rat

1. Anaesthetized rats were given [3H]orotic acid either intraperitoneally or via a catheter into the hepatic artery with or without degradable starch microspheres. 2. The radioactivity in the acid soluble and RNA fractions of five pieces of the left lateral liver lobes was determined. 3. A variation of the distribution of the precursor into the different parts of the same liver lobe was shown. 4. This variation was most pronounced (3000-17,000 cpm/micrograms in the acid soluble fraction) when the precursor was administered via the artery and without microspheres. 5. The correlation between the radioactivity in the acid soluble and RNA fractions within each liver piece was 0.85, 0.90 and 0.75 in the three groups respectively. 6. It is suggested that the variation of the distribution depends on circulatory differences within the liver.     

Evaluation of microencapsulation of a Bifidobacterium strain with starch as an approach to prolonging viability during storage

AIMS: To optimize a spray coating process for the production of encapsulated microspheres containing viable Bifidobacterium cells and to determine whether the readily gelatinized modified starch coating used in this study improved bacterial survival in foods or under acid conditions. METHODS AND RESULTS: An air inlet temperature of 100 degrees C was demonstrated to be optimal for the spray drying process, as it afforded good drying, low outlet temperatures (45 degrees C) and resulted in less than 1 log reduction in bifidobacteria numbers during drying. Maximum recovery yields of 30% were obtained after optimizing the air aspiration conditions. The average size of the Bifidobacterium PL1-containing starch microparticles was determined by scanning electron microscopy to be of the order of 5 microm. The starch-coated cells did not display any enhanced viability compared with free PL1 cells when exposed to acid conditions for 6 h or in two dry food preparations over 20 d storage at ambient temperature (19-24 degrees C). Determination of 1491 nucleotides of the 16S rRNA gene from PL1 indicated that it shared 97% homology with a previously sequenced Bifidobacterium ruminantium strain. CONCLUSIONS: Our data demonstrated that, although spray drying is a valuable process for encapsulating bifidobacteria, further work is required to ascertain a more appropriate coating material that will protect this strain against adverse environmental conditions. SIGNIFICANCE AND IMPACT OF THE STUDY: The production of small, uniformly coated microspheres containing viable bifidobacteria using an affordable and industrially convenient process, such as spray drying, has commercial implications for the production of probiotic products. Although popular for use as a coating polymer by the food industry, this study indicated that modified starches might not be suitable for use as an encapsulating material for probiotic strains.     

胶原酶缓释微球的研究

目的:本实验旨在开发一种胶原酶缓释微球制剂,用以治疗手掌腱膜挛缩症,以减小现有水针剂的不足。方法:利用水相-水相乳化法和低温冷冻相分离法两种方法制备载药颗粒,分别将其包裹于PLGA微球内,制备成胶原酶微球,并用扫描电镜考察其表面形态,对其粒径进行统计学分析,测定体外释放行为并比较。结果:两种方法制备的微球表面光滑圆整,都可以达到缓释的效果,一个星期内释药完全。水相-水相乳化法制备的微球比低温冷冻相分离制备的微球粒径大,且具有统计学差异(P0.05)。水相-水相乳化法制备的微球粒径较均一,其体外释放更加平缓,突释较小。结论:本研究制得的胶原酶微球能实现理想的体外缓释效果,解决了现有技术中胶原酶粉针剂型快速释放并分散的问题。     

Implication of activation of intraperitoneal macrophages with bio-degradable microspheres

To estimate the possibility that biological degradable starch microspheres (DMS) activate abdominal or intraperitoneal macrophages (IMP), two sizes of DMS (Spherex, Pharmacia, Sweden) were injected into the peritoneum of the ICR mice of 4 to 8 weeks of age. Three days after the injection, peritoneal fluid was collected and incubated for one hour at 37 degrees C under 5% CO2. The cells which adhered to the petri dish were IMP, to which DMS was added for 18 hrs. The cultured IMP were observed by scanning electron microscope (SEM) and the ratio of the active type to the total number of IMP was counted as an index of the effect of DMS to IMP. The activation effect of DMS on the incubated IMP was significant in the group which was cultured with 2 microns DMS after the 45 microns DMS injection. That indicated the possible DMS function as a potential IMP activating factor (MAF).